<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1">
    <link href="https://fonts.googleapis.com/css2?family=Titillium+Web:wght@400;600&display=swap" rel="stylesheet">
    <title>News - Ora Biomedical, Inc.</title>
    <link rel="stylesheet" href="css/styles.css">
</head>
<body>
      

    <header>
        <img id="OraLogo_Home" src="images/OraBiomedical.png" alt="Ora Biomedical">
        <nav>
            <ul>
                <li><a href=" "> </a></li>
                <li><a href=" "> </a></li>
                <li><a href=" "> </a></li>
                <li><a href=" "> </a></li>
                <li><a href="news.html">News</a></li>
                <li><a href="science.html">Science</a></li>
                <li><a href="company.html">Company</a></li>
                <li><a href="MMC.html">Million Molecule Challenge</a></li>
                <li><a href="contact.html">Contact</a></li>
                <li><a href="shoppingcart.html">Shopping Cart</a></li>
            </ul>
        </nav>
    </header>

        <main>
            <h1>Company and Research News</h1>
            <h2>The latest news from Ora Biomedical, longevity biotechnology, 
                and geroscience breakthroughs.</h2>
        </main>

    <div>

        <div class="wave-container">
            <canvas class="wave-canvas"></canvas>
            <div class="wave-content">
                <h1>Ora Biomedical awarded NIH Small Business Innovation Research 
                    technology development grant</h1>

                <div id="right">
                    <img src="images/news2.png" alt="news2" style="width:300px">
                </div>

                <div id="left">
                    <h2><em>September 2, 2024</em></h2>
                    <p>Ora Biomedical announced that it has been selected for a
                        Small Business Innovation Research (SBIR) Phase I grant
                        from the National Institutes of Health (NIH). The technology development grant awarded through the 
                        National Institute on General Medical Sciences (NIGMS) will support 
                        development of EleGantry, an innovative software and hardware 
                        infrastructure designed to enhance rigor and reproducibility in 
                        invertebrate research, with a particular focus on longevity studies 
                        using Caenorhabditis elegans (C. elegans). 
                    </p>
                    <p>Read the article
                        <a href="https://orabiomedical.com/wp-content/uploads
                        /2024/09/ElegantrySBIR_PressRelease.pdf">here.</a></p>

                </div>
            </div>
        </div>

        <div class="wave-container">
            <canvas class="wave-canvas"></canvas>
            <div class="wave-content">
                <h1>Ora Biomedical partners with the U.S. Air Force to develop 
                    protective space radiation therapeutics based on longevity 
                    science</h1>

                <div id="right">
                    <img src="images/news3.png" alt="news3" style="width:300px">
                </div>

                <div id="left">
                    <h2><em>May 28, 2024</em></h2>
                    <p>Ora Biomedical has been selected by AFWERX, the 
                        innovation arm of the Department of the Air Force 
                        powered by the Air Force Research Laboratory (AFRL), 
                        for a Phase I SBIR grant to develop novel therapeutics 
                        to protect astronauts and high-altitude pilots from 
                        elevated space radiation based on its work identifying 
                        and developing age-targeting longevity interventions. 
                    </p>
                    <p>Read the article <a href="https://orabiomedical.com/
                        wp-content/uploads/2024/05/SBIR-Phase-I-Press-Release.pdf">here</a>.</p>
                </div>
            </div>
        </div>

        <div class="wave-container">
            <canvas class="wave-canvas"></canvas>
            <div class="wave-content">
                <h1>Ora Biomedical partners with Lifespan.io to fiscally 
                    sponsor the Million Molecule Challenge</h1>

                <div id="right">
                    <img src="images/news4.png" alt="news4" style="width:450px">
                </div>

                <div id="left">
                    <p>Lifespan.io is a leading nonprofit advocacy foundation 
                        and online platform committed to advancing the science
                        of aging and promoting healthy human lifespan. By 
                        supporting groundbreaking research projects, 
                        disseminating educational resources, and raising public 
                        awareness about the importance of longevity, 
                        Lifespan.io aims to accelerate the development of 
                        therapies that can improve the quality of life for 
                        people worldwide. With a focus on collaboration and 
                        innovation, Lifespan.io is driving the conversation 
                        on aging research and transforming the way we approach 
                        health and wellness throughout our lives. For more 
                        information, please visit 
                        <a href="https://www.lifespan.io/">Lifespan.io.</a>
                    </p>
                </div>
            </div>
        </div>

        <div class="wave-container">
            <canvas class="wave-canvas"></canvas>
            <div class="wave-content">
                <h1>Ora Biomedical announces Optispan Ventures as Lead Investor
                    in Pre-Seed Financing</h1>

                    <h2><em>August 29, 2022</em></h2>
                    <p>Seattle, WA – Ora Biomedical, Inc., is proud to announce
                         an investment deal with Optispan Ventures that 
                         includes financing and research headquarters to build 
                         a high-throughput longevity drug discovery facility in 
                         the Pacific Northwest. Optispan Ventures is focused on
                          healthspan innovations that will define 21st Century 
                          Medicine. “Interventions that target the biology of 
                          aging have the potential to dramatically improve 
                          quality of life by increasing healthspan – a healthy, 
                          disease-free lifespan is the goal. We are pleased to 
                          partner with Ora to apply their game-changing 
                          Wormbot-AI technology and go far beyond what has 
                          previously been possible in this field”, says Stuart 
                          McKee, CEO of Optispan.Optispan Ventures and Ora 
                          Biomedical have a shared vision of revolutionizing 
                          how we age” says Ora Biomedical CEO, Dr. Mitchell 
                          Lee. “Thanks to our partnership with Optispan, we can
                           accelerate the launch of our longevity drug 
                           discovery factory and move one step closer to 
                           developing breakthrough healthy aging therapeutics 
                           for humans and all other animals we love.” For more 
                           information, see full 
                        <a href="https://orabiomedical.com/wp-content/uploads/
                        2022/08/PRESS-RELEASE_Ora-Optispan_08292022-1.pdf">Press Release</a>
                    </p>

                    <img src="images/news5.png" alt="news5" style="width:450px">
            </div>
        </div>

    </div>
    <script src="js/scripts.js"></script>

</body>
</html>
